WeVote

Bill

Bill

SB 126

INS CD-ALZHEIMER'S TREATMENT

104th Regular Session Introduced by Carol Ammons and 59 co-sponsors

Illinois requires insurance coverage of FDA-approved Alzheimer's treatments without prior authorization, effective immediately with full implementation by July 2027.

Public Act . . . . . . . . . 104-0001
0
WeVote Research Nonpartisan
Bill Summary · SB 126

Legislative bill overview

SB 126 requires Illinois insurance carriers to cover Alzheimer's disease treatments, including disease-modifying monoclonal antibody therapies, without prior authorization requirements or excessive cost-sharing barriers. The bill establishes coverage standards and removes administrative obstacles to accessing emerging Alzheimer's treatments that have received FDA approval.

Why is this important

Alzheimer's disease affects over 120,000 Illinoisans, and newer treatments like aducanumab and lecanemab show promise in slowing cognitive decline in early-stage patients. By mandating insurance coverage without prior authorization delays, the bill aims to improve access to these treatments while reducing out-of-pocket costs that could otherwise prevent eligible patients from receiving them.

Potential points of contention

  • Cost implications: Insurance carriers may argue that mandated coverage without cost controls could significantly increase premiums for all policyholders
  • Prior authorization debate: While removing prior authorization speeds access, insurers contend these requirements help prevent inappropriate use and ensure medical necessity
  • Limited eligibility criteria: The bill may still restrict coverage to specific patient populations (early-stage disease, certain cognitive test scores), leaving some patients unable to access treatments despite diagnosis
  • Clinical evidence uncertainty: Some treatments remain expensive while long-term effectiveness data is still accumulating, raising questions about cost-benefit ratios

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.